Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss.
Nieves Mata-CastroLorena Sanz-LópezDavid Varillas-DelgadoAlfredo García-FernándezPublished in: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2019)
Infliximab intratympanic infiltration improves the hearing threshold in patients with immune-mediated hearing loss. The effect of improving the hearing threshold is higher in low frequencies and persists within 3 months of the infiltration. The administration of intratympanic infliximab is an effective and safe technique.
Keyphrases